Clinical TrialsThe additional cohort in the ongoing Phase 2 trial of atumelnant includes morning dosing, which may provide greater dosing flexibility and potentially better disease control.
Market CompetitionPaltusotone is expected to receive a broad label and uniform reimbursement for both the first-line 'treatment' setting and second-line 'maintenance' setting, enabling access without first attempting first-generation somatostatin analogs.
Pipeline DevelopmentCRNX plans to start Phase 3 trials in adults and pediatric CAH patients next year, indicating further progress and development.